Exclusive: Following a severe setback, BridgeBio brings out the budget axe to chop staff but keeps quiet on the numbers
Three months after BridgeBio’s TTR amyloidosis candidate suffered a major — and according to CEO Neil Kumar, “baffling” — Phase III fail that wiped out $4 billion in market cap, Endpoints News has learned that the company is swinging the budget axe, all while lying low as best it can during the restructuring.
After receiving a call and tracking social media posts regarding a number of layoffs at BridgeBio, Kumar confirmed that the company has made cuts without specifying just how many.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.